
  
    
      
        
        The_DT Icelandic_NNP population_NN is_VBZ now_RB a_DT part_NN of_IN a_DT unique_JJ epidemiological_JJ study_NN ,_, which_WDT has_VBZ
        involved_VBN investigating_VBG the_DT genetic_JJ heritage_NN of_IN many_JJ of_IN them_PRP ._. The_DT reason_NN that_IN this_DT
        experiment_NN can_MD be_VB done_VBN is_VBZ because_IN of_IN the_DT remarkable_JJ records_NNS that_WDT exist_VBP in_IN Iceland_NNP ._. Not_RB only_RB
        is_VBZ there_EX almost_RB complete_JJ genealogical_JJ information_NN dating_VBG back_RB to_TO the_DT 18_CD th_NN century_NN on_IN all_DT
        current_JJ (_( 288_CD ,_, 000_CD )_) and_CC many_JJ previous_JJ Icelanders_NNP (_( more_JJR than_IN 600_CD ,_, 000_CD in_IN total_JJ )_) ,_, but_CC in_IN
        addition_NN the_DT country_NN has_VBZ an_DT almost_RB complete_JJ cancer_NN registry_NN dating_VBG from_IN 1955_CD ._. A_DT company_NN ,_,
        deCODE_NN Genetics_NNP ,_, was_VBD set_VBN up_RP to_TO mine_NN health-care_NN data_NNS in_IN Iceland_NNP ,_, and_CC to_TO use_VB it_PRP to_TO assess_VB
        the_DT effect_NN of_IN genetics_NNS on_IN health_NN ._. Initially_RB ,_, the_DT company_NN attracted_VBD criticism_NN ,_, with_IN some_DT
        questioning_VBG the_DT ethics_NNS of_IN providing_VBG access_NN to_TO health-care_NN data_NNS for_IN many_JJ disease_NN projects_NNS to_TO
        a_DT for-profit_JJ company_NN ._. But_CC the_DT company_NN has_VBZ been_VBN supported_VBN by_IN many_JJ Icelanders_NNP themselves_PRP ,_,
        demonstrated_VBN by_IN Icelanders_NNP donating_VBG blood_NN samples_NNS with_IN informed_VBN consent_NN for_IN research_NN on_IN
        multiple_JJ diseases_NNS ,_, and_CC now_RB the_DT project_NN 's_POS scientific_JJ value_NN is_VBZ becoming_VBG apparent_JJ ._.
        One_CD such_JJ analysis_NN is_VBZ the_DT subject_NN of_IN a_DT paper_NN by_IN Laufey_NNP Amundadottir_NNP and_CC colleagues_NNS in_IN
        this_DT month_NN 's_POS 
        PLoS_NNP Medicine_NNP that_IN assesses_NNS how_WRB much_JJ genetic_JJ factors_NNS contribute_VBP to_TO cancer_NN
        risk_NN across_IN the_DT whole_JJ Icelandic_NNP population_NN ._.
        The_DT paper_NN looked_VBD at_IN 27_CD different_JJ types_NNS of_IN cancers_NNS (_( all_PDT those_DT with_IN more_JJR than_IN 200_CD cases_NNS )_)
        that_WDT had_VBD been_VBN registered_VBN between_IN 1955_CD and_CC 2002_CD and_CC analysed_JJ the_DT frequency_NN of_IN close_JJ and_CC
        distant_JJ relatives_NNS also_RB having_VBG that_DT cancer_NN ,_, or_CC another_DT kind_NN of_IN cancer_NN ._. Of_IN the_DT 27_CD cancers_NNS ,_, 16_CD
        showed_VBD significant_JJ “ familiality_NN ,_,” and_CC for_IN some_DT this_DT risk_NN even_RB extended_VBD to_TO distant_JJ (_( that_WDT is_VBZ ,_,
        third-_NN to_TO fifth-degree_JJ )_) relatives_NNS ._. The_DT seven_CD cancers_NNS with_IN the_DT highest_RBS increased_VBN familial_NN
        occurrence_NN both_DT in_IN close_JJ and_CC distant_JJ relatives_NNS were_VBD breast_NN ,_, prostate_NN ,_, stomach_NN ,_, lung_NN ,_, colon_NN ,_,
        kidney_NN ,_, and_CC bladder_NN cancers_NNS ._. And_CC ,_, interestingly_RB ,_, three_CD cancers—stomach_NN ,_, lung_NN ,_, and_CC colon_NN
        cancer—were_NN also_RB seen_VBN more_RBR frequently_RB in_IN mates_NNS of_IN patients_NNS ,_, indicating_VBG a_DT shared_VBN
        environmental_JJ risk_NN factor_NN ._. And_CC for_IN some_DT cancers_NNS there_RB was_VBD a_DT familial_NN association_NN with_IN other_JJ
        cancers_NNS ,_, for_IN example_NN ,_, relatives_NNS of_IN individuals_NNS with_IN stomach_NN ,_, colon_NN ,_, rectal_NN ,_, or_CC endometrial_NN
        cancer_NN were_VBD more_RBR likely_JJ to_TO have_VB any_DT of_IN these_DT cancers_NNS ._.
        Cathryn_NNP Lewis_NNP ,_, the_DT academic_JJ editor_NN for_IN the_DT paper_NN comments_NNS on_IN the_DT study_NN 's_POS strengths_NNS ._.
        “ This_DT level_NN of_IN family_NN relationship_NN and_CC clinical_JJ diagnosis_NN is_VBZ rarely_RB available_JJ from_IN
        interviewing_VBG patients_NNS and_CC family_NN members_NNS ._. The_DT size_NN of_IN the_DT study_NN (_( over_IN 600_CD ,_, 000_CD individuals_NNS ,_,
        with_IN 32_CD ,_, 000_CD cancer_NN cases_NNS )_) and_CC the_DT high_JJ quality_NN of_IN data_NNS enables_VBZ the_DT authors_NNS to_TO detect_VB subtle_JJ
        effects_NNS across_IN distant_JJ relationships_NNS ._.”
        How_WRB robust_JJ are_VBP these_DT data_NNS ,_, and_CC what_WP do_VBP they_PRP mean_VBP for_IN the_DT biological_JJ understanding_NN of_IN
        cancer_NN ?_. As_IN Lewis_NNP says_VBZ ,_, “ Although_IN the_DT current_JJ study_NN is_VBZ impressive_JJ in_IN its_PRP$ size_NN and_CC scope_NN ,_,
        even_RB here_RB ,_, the_DT sample_NN size_NN becomes_VBZ an_DT issue_NN ,_, with_IN the_DT most_RBS convincing_JJ results_NNS seen_VBN in_IN the_DT
        most_RBS common_JJ cancers_NNS ._.” Certainly_RB not_RB all_PDT the_DT findings_NNS are_VBP surprising_VBG ;_: some_DT rare_JJ cancers_NNS are_VBP
        already_RB known_VBN to_TO be_VB associated_VBN with_IN particular_JJ genetic_JJ defects_NNS ,_, and_CC syndromes_NNS that_WDT
        predispose_VB to_TO multiple_JJ cancers_NNS have_VBP been_VBN described_VBN ,_, for_IN example_NN ,_, that_IN of_IN Hereditary_NNP
        Nonpolyposis_NNP Colorectal_NNP Cancer_NNP ._. Other_JJ associations_NNS are_VBP more_JJR intriguing—the_NN cluster_NN of_IN
        related_VBN cancers_NNS that_WDT include_VBP prostate_NN ,_, kidney_NN ,_, and_CC bladder_NN could_MD possibly_RB have_VB a_DT
        developmental_NN origin_NN ,_, since_IN all_DT arise_VBP from_IN the_DT same_JJ part_NN of_IN the_DT embryo_NN ._.
        So_RB ,_, by_IN highlighting_VBG these_DT subtle_JJ links_NNS ,_, the_DT study_NN 's_POS particular_JJ value_NN may_MD become_VB
        apparent_JJ :_: deciding_VBG future_JJ avenues_NNS of_IN investigation_NN in_IN the_DT complex_JJ interrelationships_NNS that_WDT
        interact_NN to_TO produce_VB cancer_NN ._.
      
    
  
